On November 15, 2021 IKENA Oncology (IKENA; Boston, MA, USA) reported that an investigator-initiated trial of IK-007 (AskAt’s EP4 antagonist AAT-007) in metastatic inflammatory breast cancer was launched in September 2021, led by Naoto Ueno, M.D., of the University of Texas MD Anderson Cancer Center(Press release, AskAt, NOV 15, 2021, View Source [SID1234595538]). The company made this announcement in its Third Quarter 2021 financial results and corporate update.